This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, P. O. Articles by Connell, J. M. C. Search for Related Content PubMed PubMed Citation Articles by Lim, P. O. Articles by Connell, J. M. C.

Variation at the Aldosterone Synthase (CYP11B2) Locus Contributes to Hypertension in Subjects with a Raised Aldosterone-to-Renin Ratio

Hypertension Research Centre (P.O.L., T.M.M.), Directorate of Biochemical Medicine (E.Do.), Department of Endocrinology (R.T.J.), Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom; Medical Research Council Blood Pressure Group (C.H., E.F., N.H.A., E.Da., R.F., J.M.C.C.), Western Infirmary, Glasgow, G11 6NT, United Kingdom; and Department of Cardiology (P.O.L.), Wales Heart Research Institute, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom

Abstract

The aldosterone-to-renin ratio (ARR) is a marker of aldosterone activity in hypertension. We examined the relationship of the ARR to the distribution of two biallelic polymorphisms at the CYP11B2 gene locus. One polymorphism affects a putative steroidogenic factor-1 binding site (-344 T/C) in the 5'-regulatory region, whereas the other marker reflects replacement of the intron-2 from CYP11B2 with that from the neighboring gene encoding 11ß-hydroxylase (CYP11B1; wild-type/conversion). We studied consecutive referrals to the Tayside hypertension clinic in 1998. Because the specificity of ARR (pmol/liter/ng/ml/h) for hyperaldosteronism increases with its threshold, ARRs of at least 750 and 1000 were used. A total of 375 patients were assessed; 86.9% had complete data. There were significant excesses of steroidogenic factor-1 (T) (ARR 750, 0.62 vs. 0.51, P = 0.014; ARR 1000, 0.63 vs. 0.51, P = 0.039) and intron-2 (conversion) (ARR 750, 0.49 vs. 0.41, P = 0.205; ARR 1000, 0.54 vs. 0.41, P = 0.029) alleles in patients with a raised ARR. The odds ratio for a raised ARR was 2.27 [95% confidence interval, 1.01, 5.09; P < 0.05] comparing patients with a homozygous haplotype for these alleles with those without any such alleles, and this risk increased with age. This study supports the notion that there is a genetic component that regulates aldosterone production and that hyperaldosteronism might develop over time in susceptible individuals.

This article has been cited by other articles:

				G. Escher, M. Cristiano, M. Causevic, M. Baumann, F. J. Frey, D. Surbek, and M. G. Mohaupt High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1870 - 1875. [Abstract] [Full Text] [PDF]

				J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]

				D. A. Calhoun and N. M. Kaplan Is There an Unrecognized Epidemic of Primary Aldosteronism? (Pro) Hypertension, September 1, 2007; 50(3): 447 - 453. [Full Text] [PDF]

				N. Iwai, K. Kajimoto, H. Tomoike, and N. Takashima Polymorphism of CYP11B2 Determines Salt Sensitivity in Japanese Hypertension, April 1, 2007; 49(4): 825 - 831. [Abstract] [Full Text] [PDF]

				M. Barr, S. M. MacKenzie, E. C. Friel, C. D. Holloway, D. M. Wilkinson, N. J.R. Brain, M. C. Ingram, R. Fraser, M. Brown, N. J. Samani, et al. Polymorphic Variation in the 11{beta}-Hydroxylase Gene Associates With Reduced 11-Hydroxylase Efficiency Hypertension, January 1, 2007; 49(1): 113 - 119. [Abstract] [Full Text] [PDF]

				D. M. McNamara, S. W. Tam, M. L. Sabolinski, P. Tobelmann, K. Janosko, A. L. Taylor, J. N. Cohn, A. M. Feldman, and M. Worcel Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure: Results From the A-HeFT Trial J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1277 - 1282. [Abstract] [Full Text] [PDF]

				A. J Casal, V. J P Sinclair, A. M Capponi, J. Nicod, U. Huynh-Do, and P. Ferrari A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity. J. Mol. Endocrinol., August 1, 2006; 37(1): 71 - 80. [Abstract] [Full Text] [PDF]

				D. Gu, S. Su, D. Ge, S. Chen, J. Huang, B. Li, R. Chen, and B. Qiang Association Study With 33 Single-Nucleotide Polymorphisms in 11 Candidate Genes for Hypertension in Chinese Hypertension, June 1, 2006; 47(6): 1147 - 1154. [Abstract] [Full Text] [PDF]

				S. Ganapathipillai, G. Laval, I. S. Hoffmann, A. M. Castejon, J. Nicod, B. Dick, F. J. Frey, B. M. Frey, L. X. Cubeddu, and P. Ferrari CYP11B2-CYP11B1 Haplotypes Associated with Decreased 11{beta}-Hydroxylase Activity J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1220 - 1225. [Abstract] [Full Text] [PDF]

				B. Keavney, B. Mayosi, N. Gaukrodger, H. Imrie, M. Baker, R. Fraser, M. Ingram, H. Watkins, M. Farrall, E. Davies, et al. Genetic Variation at the Locus Encompassing 11-{beta} Hydroxylase and Aldosterone Synthase Accounts for Heritability in Cortisol Precursor (11-Deoxycortisol) Urinary Metabolite Excretion J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1072 - 1077. [Abstract] [Full Text] [PDF]

				O. Olivieri, A. Ciacciarelli, D. Signorelli, F. Pizzolo, P. Guarini, C. Pavan, A. Corgnati, S. Falcone, R. Corrocher, A. Micchi, et al. Aldosterone to Renin Ratio in a Primary Care Setting: The Bussolengo Study J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4221 - 4226. [Abstract] [Full Text] [PDF]

				E. M. Freel and J. M.C. Connell Mechanisms of Hypertension: The Expanding Role of Aldosterone J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1993 - 2001. [Abstract] [Full Text] [PDF]

				P. C. White Aldosterone: Direct Effects on and Production by the Heart J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2376 - 2383. [Full Text] [PDF]

				J. Nicod, D. Bruhin, L. Auer, B. Vogt, F. J. Frey, and P. Ferrari A Biallelic Gene Polymorphism of CYP11B2 Predicts Increased Aldosterone to Renin Ratio in Selected Hypertensive Patients J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2495 - 2500. [Abstract] [Full Text] [PDF]

				J. M.C. Connell, R. Fraser, S. MacKenzie, and E. Davies Is Altered Adrenal Steroid Biosynthesis a Key Intermediate Phenotype in Hypertension? Hypertension, May 1, 2003; 41(5): 993 - 999. [Abstract] [Full Text] [PDF]